ClinicalTrials.gg
RecruitingNCT06769191Updated Jan 20, 2025

Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell Sequential Allo-HSCT and Kidney Transplantation in the Treatment of SIOD

An Early Phase 1 interventional study of CD7 CAR-T cells injection and Allo-HSCT in Schimke Immuno-osseous Dysplasia, sponsored by Zhejiang University. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2025-01-20.

Sponsored by Zhejiang University · Early Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Sex
All
01

Study summary

A Clinical Study on the Safety and Effectiveness of CD7 CAR-T Cell Sequential Allo-HSCT and Kidney Transplantation in the treatment of Schimke immuno-osseous dysplasia

Read the detailed description

This is a single-arm, open-label, dose-escalation clinical trial to evaluate the safety and efficacy of CD7 CAR-T Cell Sequential Allo-HSCT and Kidney Transplantation in patients with Schimke immuno-osseous dysplasia. It is planned to enroll 20 participants in this trial.

02

Conditions studied

  • Schimke Immuno-osseous Dysplasia

Keywords

  • CAR-T
  • Allo-HSCT
  • Kidney Transplantation
03

In context

Lead sponsor

Zhejiang University is the lead sponsor of 357 studies on the registry; 167 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Diagnosed as SIOD and was in stage 5 of chronic kidney disease
    1. Having HSCT indications, at least suitable donors (relatives) for haploidentical allogeneic transplantation and kidneys from stem cell transplantation donors;
    1. serum total ≤ 1.5 times the , and serum (ALT) and aspartate aminotransferase (AST) were both ≤ 3 times the upper limit of the normal range.
    1. Echocardiogram shows (LVEF) ≥ 50%;
    1. There is no active pulmonary infection, and the oxygen saturation during air inhalation is more than 92%;
    1. Estimated survival time ≥ 3 months;
    1. performance status 0 to 1;
    1. Pregnant/lactating women, or male or female patients who have fertility and are willing to take effective measures at least 6 months after the last cell infusion during the study period;
    1. Those who voluntarily participated in this trial and provided ;

Exclusion criteria

Exclusion Criteria:

    1. Allergic to pretreatment measures
    1. received any containing ATG/ALG such IST、alemtuzumab、high-dose cyclophosphamide (≥ 45mg/kg/day) , received CsA treatment within 6 months, or used thrombopoietin receptor (tpo-r) agonists in the past;
    1. Patients with the history of epilepsy or other CNS disease;
    1. Patients with prolonged time or severe heart disease;
    1. Previous recipients of hematopoietic stem cell transplantation or organ transplantation
    1. People infected with , active or virus, and patients with active infection who are not cured;
    1. The proiferation rate is less than 5 times response to CD3/CD28 co-stimulation signal;
    1. Patients with malignant tumor;
    1. People with other genetic diseases;
    1. After receiving CD7 car-t treatment, patients who were unable to accept subsequent kidney transplantation due to severe infection or poor amplification of car-t in vivo.
    1. Any situation that researchers believe may increase the risk to the subjects or interfere with the trial results.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Treatment Group

    Schimke Immuno-osseous Dysplasia

    Biological: CD7 CAR-T cells injection · Procedure: Allo-HSCT · Procedure: Kidney Transplantation

Interventions

  • BiologicalAnti-CD7 CAR T-cellsStudies of Anti-CD7 CAR T-cellsAnti-CD7 CAR T-cells pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intravenous infusion, single dose

  • ProcedureAllo-HSCT

    allogeneic hematopoietic stem cell transplantation

  • ProcedureKidney Transplantation

    Kidney Transplantation

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs)

    Incidence of treatment-emergent adverse events

    Time frame: Up to 2 years after Treatment

  2. Transplant related mortality rate

    The proportion of patients who died after transplantation to the total number of transplant patients during the same period

    Time frame: Up to 100 days after Treatment

Secondary outcomes

  1. Allogeneic hematopoietic stem cell transplant implantation rate

    The proportion of the number of patients who achieved hematopoietic reconstitution to the total number of allogeneic hematopoietic stem cell transplantation patients in the same period.

    Time frame: Up to 100 days after Treatment

  2. Kidney transplantation implantation rate

    The ratio of successfully implanted kidneys to the total implanted kidneys

    Time frame: Up to 100 days after Treatment

  3. Time to neutrophil and platelet engraftment

    The time for neutrophils and platelets to reach the implantation criteria after stem cell reinfusion

    Time frame: Up to 30 days after Treatment

  4. Disease-feesurvival,DFS

    The proportion of disease-free patients who survived to the total number of patients who transplanted allogeneic hematopoietic stem cells during the same period.

    Time frame: Up to 2 years after Treatment

  5. Overall survival, OS

    After transplantation until death from any cause.

    Time frame: Up to 2 years after Treatment

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2025; primary completion for Jan 2028, 36 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2025
First posted
Jan 10, 2025
StartEst.
Jan 30, 2025
Primary completionEst.
Jan 30, 2028
CompletionEst.
Jan 30, 2028
Last update
Jan 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06769191
Collaborators
Yake Biotechnology Ltd.
Responsible party
He Huang (Principal Investigator, First Affiliated Hospital of Zhejiang University) — Principal investigator
First posted
Jan 10, 2025
Start date
Jan 30, 2025 (estimated)
Primary completion
Jan 30, 2028 (estimated)
Completion
Jan 30, 2028 (estimated)
Last update
Jan 20, 2025

Study contacts

He Huang, MD
Contact
hehuangyu@126.com
057187233772
Yongxian Hu, MD
Contact
huyongxian2000@aliyun.com
057187233772
He Huang, MD
principal investigator · Zhejiang University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CD7 CAR T-cells

Start the discussion